Images for illustrative purposes only
Looking for Next Day delivery?
Order before 15:30 on Monday to Friday for next day delivery
Foundayo Pill
Orforglipron is a once-daily GLP-1 receptor agonist tablet developed by Eli Lilly, sold under the brand name Foundayo. On 10 August 2026 the UK's Medicines and Healthcare products Regulatory Agency (MHRA) authorised it for weight management and type 2 diabetes, making the UK the first country in Europe to approve this GLP-1 tablet [12].
- Once-daily tablet with no needles and no refrigeration, and no food or water timing restrictions, unlike the Wegovy tablet [2,3]
- Average 11.2% body weight reduction at the 36 mg dose over 72 weeks in the ATTAIN-1 trial, though trial doses are not the licensed strengths [4]
- Prescription-only medicine, not available over the counter
- MHRA-authorised in the UK but not yet available on the NHS, where use will follow a NICE evaluation (appraisal expected 18 November 2026) [6,12]
Last updated: 11 August 2026
Can you buy orforglipron in the UK?
Yes, in principle. On 10 August 2026 the Medicines and Healthcare products Regulatory Agency (MHRA) granted orforglipron (Foundayo) a marketing authorisation, making the UK the first country in Europe to approve this GLP-1 tablet for weight management and type 2 diabetes [12]. It can now be legally prescribed and supplied in the UK.
Orforglipron is a prescription-only medicine, so it can only be obtained from a registered pharmacy with a prescription from a registered prescriber.
It is not available on the NHS at this time, and any future NHS use will follow the usual process, including an evaluation by the National Institute for Health and Care Excellence (NICE). A private prescription route is possible now that the medicine holds a UK licence, subject to it being available to supply.
We will add orforglipron to our prescribing range once our prescribers are satisfied it is appropriate to offer and stock is available to supply.
What is orforglipron?
Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist taken as a once-daily tablet [2]. It was discovered by Chugai Pharmaceutical and licensed to Eli Lilly in 2018 [2]. In the United States it is sold as Foundayo; orforglipron is the generic drug name, and you will see both used interchangeably.
The distinction that matters clinically is “small molecule” versus “peptide”. Semaglutide - the active ingredient in Wegovy, Ozempic and Rybelsus - is a peptide, which is why oral semaglutide has to be taken on an empty stomach with strict timing rules around food and drink [1]. Orforglipron is a small molecule, so it survives digestion without those constraints and can be taken at any time of day, with or without food or water [2,3].
The US licence covers adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition, alongside a reduced-calorie diet and increased physical activity [3].
How does orforglipron work?
Orforglipron mimics glucagon-like peptide-1 (GLP-1), a hormone released by the gut after eating. Activating the GLP-1 receptor produces three effects that together support weight reduction [2,3]:
- Reduced appetite. GLP-1 signalling in the brain lowers hunger and reduces intrusive thoughts about food.
- Slower gastric emptying. Food stays in the stomach longer, so fullness lasts longer after a meal.
- Improved glucose handling. Insulin secretion increases in response to raised blood glucose.
As with every GLP-1 medicine, orforglipron is intended to be used alongside a reduced-calorie diet and increased physical activity, not instead of them [3].
How effective is orforglipron?
The evidence base is the ATTAIN Phase 3 programme, which enrolled more than 4,500 adults with obesity or overweight across two registration trials [2].
ATTAIN-1: the main weight loss trial for orforglipron
In the ATTAIN-1 trial, 3,127 adults took either orforglipron (Foundayo) or a dummy tablet (placebo) every day for 72 weeks - around 17 months. Everyone in the trial was living with obesity, or with overweight plus at least one related health condition such as high blood pressure or sleep apnoea. Nobody had diabetes.
Those on orforglipron were given one of three daily doses: 6 mg, 12 mg or 36 mg [4]. Here's how much weight each group lost on average by the end [4]:
| Dose | Mean weight change at 72 weeks |
|---|---|
| Orforglipron 6 mg | −7.5% |
| Orforglipron 12 mg | −8.4% |
| Orforglipron 36 mg | −11.2% |
| Placebo | −2.1% |
All three doses beat placebo by a margin unlikely to be down to chance (p<0.001) [4].
You may see a higher figure of 12.4% quoted elsewhere and both numbers are correct, they just answer different questions.
- The 11.2% figure includes everyone who joined the trial, whether or not they stuck with the treatment.
- The 12.4% figure (27.3 lb) covers only those who stayed on it for the full 72 weeks [2]. The lower number is the more realistic guide to what happens in practice.
Among people on the highest dose who stayed on treatment, 59.6% lost at least 10% of their body weight and 39.6% lost at least 15% [4].
Orforglipron also improved several markers of cardiovascular risk across all doses, including waist circumference, non-HDL cholesterol, triglycerides and systolic blood pressure [2].
Of the 1,127 participants who had prediabetes when they started, up to 91% on orforglipron had near-normal blood glucose by 72 weeks, compared with 42% on placebo [4].
ATTAIN-MAINTAIN: keeping weight off after injections
Weight regain after stopping an injectable GLP-1 is one of the harder problems in obesity treatment. The Phase 3b ATTAIN-MAINTAIN trial, published in Nature Medicine in 2026, tested whether switching to an orforglipron tablet could hold the line [5].
Everyone taking part had already lost at least 5% of their body weight on tirzepatide or semaglutide injections. They then switched to either orforglipron or a placebo [5,8]:
| Previous treatment | Weight loss kept on orforgilpron | Weight loss kept on placebo |
|---|---|---|
| Tirzepatide (205 people) | 74.7% | 49.2% |
| Semaglutide (171 people) | 79.3% | 37.6% |
Over the year that followed, those who switched from semaglutide to orforglipron regained only about 1 kg of their earlier weight loss on average, while those who switched from tirzepatide regained about 5 kg [5].
How long does orforglipron take to work?
Appetite effects typically begin within the first few weeks. Because dose escalation takes a minimum of 30 days at each step, meaningful weight reduction builds gradually over several months, with the trial endpoint measured at 72 weeks [3,4].
Orforglipron dosage
The MHRA-approved schedule is a six-step titration, taken once daily at any time of day with no food or water restrictions. Treatment starts at the lowest dose, with a minimum of one month at each level before moving up [12]:
| Stage | Dose | Minimum time at this dose |
|---|---|---|
| 1 (starting dose) | 0.8 mg once daily | At least 1 month |
| 2 | 2.5 mg once daily | At least 1 month |
| 3 | 5.5 mg once daily | At least 1 month |
| 4 | 9 mg once daily | At least 1 month |
| 5 | 14.5 mg once daily | At least 1 month |
| 6 (maintenance) | 17.2 mg once daily | Ongoing |
Tablets are swallowed whole and must not be broken, crushed or chewed. Take no more than one tablet a day, and do not double up if you miss a dose. Always follow the instructions in the Patient Information Leaflet [12].
Note: the doses studied in the ATTAIN-1 trial (6 mg, 12 mg and 36 mg) are not the same as the licensed UK tablet strengths [4,12].
How much will orforglipron cost in the UK?
Orforglipron is now licensed in the UK, but it isn't available to buy yet, so we can't show a price.
The MHRA authorised it on 10 August 2026, though it is not yet available on the NHS and no UK private price has been set [12]. Any figure you see quoted online right now is speculation, so it's best not to read too much into them.
As soon as orforglipron is available to us, we'll publish our pricing right here.
Orforglipron side effects
Orforglipron was authorised by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) on 10 August 2026, under the brand name Foundayo, making the UK the first country in Europe to approve this GLP-1 tablet for weight management and type 2 diabetes.
As with all GLP-1 receptor agonists, it is a prescription-only medicine, and the MHRA has said it will keep its safety and effectiveness under close review [12].
In the US, orforglipron carries a boxed warning, the strongest type of warning on a medicine's label, about a possible risk of a type of thyroid tumour (called C-cell tumours).
Orforglipron belongs to a family of medicines known as GLP-1 receptor agonists. Some medicines in this family have caused these thyroid tumours in rats and mice during testing.
Orforglipron is a bit different: it does not act on rats and mice the same way, and it did not cause any tumours when tested in them. Even so, scientists do not yet know whether this risk, seen with other medicines in the family, applies to people, so the warning stays in place as a precaution [3].
Common side effects
Reported in 5% or more of people treated with orforglipron [3]:
- Nausea
- Constipation
- Diarrhoea
- Vomiting
- Indigestion (dyspepsia)
- Abdominal pain
- Headache
- Abdominal distension (swollen tummy)
- Fatigue
- Belching
- Heartburn (gastro-oesophageal reflux)
- Flatulence
- Hair loss
- Stomach and bowel (gastrointestinal) effects are the most frequent and are typically mild to moderate, easing as the body adjusts [4].
Serious side effects
The US prescribing information lists the following warnings and precautions [3]:
- Acute pancreatitis: stop and seek urgent medical advice if you develop severe, persistent abdominal pain, with or without vomiting
- Severe gastrointestinal reactions: not recommended in people with severe gastroparesis
- Acute kidney injury from dehydration: caused by persistent vomiting or diarrhoea
- Hypoglycaemia: risk increases if taken with insulin or a sulfonylurea
- Serious hypersensitivity reactions, including anaphylaxis and angioedema
- Diabetic retinopathy complications in people with type 2 diabetes
- Acute gallbladder disease
- Pulmonary aspiration during general anaesthesia or deep sedation: tell your healthcare team before any planned procedure
- Anyone in the UK experiencing a suspected side effect from any medicine should report it through the MHRA Yellow Card scheme [10].
Who cannot take orforglipron
Orforglipron is contraindicated in people with [3]:
- A personal or family history of medullary thyroid carcinoma (MTC)
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Known serious hypersensitivity to orforglipron or any of its excipients
- It should also be avoided in pregnancy, as it may cause foetal harm and should be stopped when pregnancy is recognised. Breastfeeding is not recommended during treatment [2,3].
Interactions that are easy to miss
1. The contraceptive pill. Orforglipron can make the combined oral contraceptive pill less effective. The US labelling advises switching to a non-oral method, or adding a barrier method (such as condoms), for 30 days after starting treatment and for 30 days after each dose increase [2,3].
2. Medicines processed by the liver (CYP3A4). Your body breaks down orforglipron using a processing system in the liver called CYP3A4. Some medicines interfere with it:
- Medicines that slow this system down (a "strong CYP3A4 inhibitor") can cause orforglipron to build up, so the dose is capped at 9 mg a day to stay safe.
- Medicines that speed it up (a "strong CYP3A4 inducer") can clear orforglipron too quickly and make it less effective, so they should be avoided.
- Simvastatin. With this common cholesterol medicine, you should not take more than 20 mg a day while on orforglipron.
3. Other tablets in general. Orforglipron slows how quickly your stomach empties, so tablets pass through more slowly. This can affect how well other tablets are absorbed [3].
4. Other weight-loss or diabetes injections. Taking orforglipron alongside another GLP-1 receptor agonist is not recommended [3].
The bottom line: orforglipron does not mix neatly with every medicine, so some doses need adjusting. Always tell your doctor or pharmacist everything else you take, including the pill and any supplements.
Is Foundayo available in the UK?
Foundayo (the brand name for orforglipron) now holds a UK marketing authorisation, granted by the MHRA on 10 August 2026 [12]. Being licensed is not the same as being in stock, though, so it may not be available to order straight away.
Where can I buy orforglipron in the UK?
Once it reaches pharmacies, orforglipron will be available on private prescription from registered pharmacies. It is a prescription-only medicine, so it cannot be sold over the counter, and anyone offering it without a prescription or through an unregulated seller is operating outside the law and poses a serious risk to your health [12].
How do I get orforglipron on prescription?
Orforglipron is a prescription-only medicine, so you will need a prescription from a doctor or another appropriately qualified prescriber. Now that it is licensed in the UK [12], it can be supplied on private prescription from a registered pharmacy once stock is available.
How much does orforglipron cost?
There is no confirmed UK price yet. We will publish our pricing on this page as soon as orforglipron is available to order from us.
Is orforglipron the same as Mounjaro?
No. Mounjaro contains tirzepatide, a peptide given as a weekly injection that acts on both the GIP and GLP-1 receptors. Orforglipron is a small-molecule daily tablet that acts on the GLP-1 receptor only. Both are made by Eli Lilly [2].
Is orforglipron better than Wegovy?
There's no head-to-head trial, so no reliable comparison can be made. In its own trials, orforglipron 36 mg produced a mean 11.2% weight reduction over 72 weeks [4]. The clearest practical difference is convenience: orforglipron has no food or water timing rules, whereas the Wegovy tablet must be taken after an 8-hour fast, with a 30-minute wait before eating or drinking [1,2].
Is orforglipron available on the NHS?
Not yet. Although orforglipron is now licensed in the UK [12], it is not currently available on the NHS. NHS use will follow the usual process, including an evaluation by NICE, which is due to publish its appraisal on 18 November 2026 [6].
What are the side effects of orforglipron?
The most common are nausea, constipation, diarrhoea and vomiting. It also carries a boxed warning for the risk of thyroid C-cell tumours, plus warnings covering pancreatitis, gallbladder disease and dehydration [3]. See the side effects section above for more detail.
Does orforglipron cause pancreatitis?
Acute pancreatitis has been reported in people taking GLP-1 receptor agonists, including orforglipron. If you develop severe, persistent abdominal pain, stop taking it and seek urgent medical advice [3].
Can I take orforglipron with my current weight loss injection?
No. Orforglipron shouldn't be taken alongside another GLP-1 medicine [3]. Never combine weight loss medicines without first speaking to your prescriber.
Is orforglipron approved for type 2 diabetes?
Yes. The MHRA authorised orforglipron for type 2 diabetes, as well as for weight management, on 10 August 2026 [12].
How will I know when orforglipron becomes available?
We update this page as soon as the position changes, so it is worth checking back here for the latest status. Bear in mind that even though a licence has now been granted, it can take time for a medicine to reach pharmacies.
Orforglipron vs Mounjaro, Wegovy and Rybelsus
The most common question about any new weight loss medicine is how it stacks up against what’s already available. The short answer is that orforglipron’s trial results sit below the leading injectables but in the same territory as the oral options - with the practical advantage of no food or water timing rules.
| Foundayo | Mounjaro | Wegovy injection | Wegovy tablet | Rybelsus | |
|---|---|---|---|---|---|
| Molecule | Orforglipron | Tirzepatide | Semaglutide | Semaglutide | Semaglutide |
| Type | Small molecule | Peptide | Peptide | Peptide | Peptide |
| How it's taken | Daily tablet | Weekly injection | Weekly injection | Daily tablet | Daily tablet |
| Food/water rules | None [2] | None | None | 8-hour fast, 30-min wait [1] | Fasted, 30-min wait |
| Refrigeration | No | Yes | Yes | No | No |
| Licensed for weight loss in UK | Yes - licensed for weight loss and type 2 diabetes [12] | Yes | Yes | Yes [1] | No - licensed for type 2 diabetes |
Orforglipron vs Mounjaro (tirzepatide)
Both are made by Eli Lilly, but they work differently. Mounjaro’s tirzepatide acts on two receptors - GIP and GLP-1 - while orforglipron acts on GLP-1 only. Mounjaro is a weekly injection requiring refrigeration; orforglipron is a daily tablet that doesn’t. In their separate trials, tirzepatide has produced larger average weight reduction.
Orforglipron vs Wegovy (semaglutide)
The Wegovy tablet is the closest comparison. Both are once-daily tablets for weight management. The practical difference is timing: the Wegovy tablet must be taken whole on an empty stomach after fasting for at least 8 hours, with a sip of water and nothing to eat or drink for 30 minutes afterwards [1]. Orforglipron has no such restrictions [2].
Orforglipron vs Rybelsus
Rybelsus is oral semaglutide, licensed in the UK for type 2 diabetes rather than weight loss. It shares the same fasting and timing requirements as other oral semaglutide products. It is not a weight loss treatment under its UK licence, so it isn’t an alternative for weight management.
What else is orforglipron being studied for?
Beyond weight management, Eli Lilly has orforglipron in trials for [2]:
- Type 2 diabetes
- Obstructive sleep apnoea
- Osteoarthritis knee pain
- High blood pressure (hypertension)
- Peripheral artery disease
- Stress urinary incontinence
In the diabetes research, a trial called ACHIEVE-1 looked at people with type 2 diabetes. It measured their HbA1c: a blood test that shows your average blood sugar over the past two to three months (the higher the number, the worse the control). Over 40 weeks, people's HbA1c dropped by 1.3% to 1.6%, starting from an average of 8.0%. In practice, that's a meaningful move in the right direction [11].
Separately, the manufacturer, Eli Lilly, says it has applied for approval of orforglipron - for weight management, type 2 diabetes, or both - in more than 40 countries [2].
When will orforglipron be available in the UK?
Orforglipron is now licensed in the UK. The MHRA authorised it for weight management and type 2 diabetes on 10 August 2026, making the UK the first country in Europe to approve this GLP-1 tablet [12].
Being licensed is not the same as being on the shelf, so it may not be available to order straight away. Eli Lilly has stated it submitted orforglipron in more than 40 countries and plans to launch shortly after approval in each, so a UK launch is expected to follow the authorisation, though the company has not confirmed an exact date [2].
So when will it be available? We cannot give a firm date yet. We will update this page, including pricing, as soon as orforglipron is available to order from us.
References
- Medicines and Healthcare products Regulatory Agency. First GLP-1 tablet for weight loss approved in the UK. GOV.UK, 11 June 2026. https://www.gov.uk/government/news/first-glp-1-tablet-for-weight-loss-approved-in-the-uk
- Eli Lilly and Company. FDA approves Lilly’s Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. 1 April 2026. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill
- Eli Lilly and Company. FOUNDAYO (orforglipron) tablets, for oral use - US Prescribing Information. US Food and Drug Administration, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). New England Journal of Medicine, 16 September 2025. doi:10.1056/NEJMoa2511774. https://www.nejm.org/doi/full/10.1056/NEJMoa2511774
- Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nature Medicine, 2026. doi:10.1038/s41591-026-04386-7. https://www.nature.com/articles/s41591-026-04386-7
- National Institute for Health and Care Excellence. Orforglipron for managing overweight and obesity [ID6516]. GID-TA11650, in development, expected publication 18 November 2026. https://www.nice.org.uk/guidance/indevelopment/gid-ta11650
- ClinicalTrials.gov. A Study of Orforglipron in Adult Participants With Obesity or Overweight (ATTAIN-1). NCT05869903. https://clinicaltrials.gov/study/NCT05869903
- ClinicalTrials.gov. A Study of Orforglipron for the Maintenance of Body Weight Reduction (ATTAIN-MAINTAIN). NCT06584916. https://clinicaltrials.gov/study/NCT06584916
- General Pharmaceutical Council. Registers. https://www.pharmacyregulation.org/registers
- Medicines and Healthcare products Regulatory Agency. Yellow Card scheme.https://yellowcard.mhra.gov.uk/
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1). New England Journal of Medicine, 2026. doi:10.1056/NEJMoa2505669. https://www.nejm.org/doi/full/10.1056/NEJMoa2505669
- Medicines and Healthcare products Regulatory Agency. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes. GOV.UK; 10 August 2026. Available from: https://www.gov.uk/government/news/uk-first-in-europe-to-authorise-orforglipron-for-weight-management-and-type-2-diabetes
